-
1 Comment
Schrödinger, Inc is currently in a long term uptrend where the price is trading 0.3% above its 200 day moving average.
From a valuation standpoint, the stock is 96.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 43.6.
Based on the above factors, Schrödinger, Inc gets an overall score of 2/5.
Exchange | NASDAQ |
---|---|
ISIN | US80810D1037 |
Sector | Healthcare |
Industry | Health Information Services |
CurrencyCode | USD |
Market Cap | 2B |
---|---|
PE Ratio | None |
Target Price | 31.7778 |
Beta | 1.77 |
Dividend Yield | None |
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for SDGR using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025